THE ROLE OF NEXT-GENERATION ANTIHYPERTENSIVE AGENTS IN THE TREATMENT OF ARTERIAL HYPERTENSION: CURRENT EVIDENCE AND CLINICAL PERSPECTIVES

Authors

Keywords:

arterial hypertension; resistant hypertension; novel antihypertensive drugs; aprocitentan; baxdrostat; lorundrostat; zilebesiran; aldosterone synthase inhibitor; RNA interference; single-pill combination.

Abstract

Arterial hypertension is a leading modifiable determinant of cardiovascular and renal morbidity, yet suboptimal blood pressure (BP) control persists despite the availability of effective conventional therapies. This narrative review critically examines the clinical efficacy, safety, and potential therapeutic positioning of next-generation antihypertensive strategies, including endothelin-receptor antagonism, aldosterone-synthase inhibition, RNA interference, and innovative single-pill combinations. International clinical guidelines, randomized controlled trials, and official United States regulatory documents available through 10 November 2026 were analyzed. In the PRECISION trial, aprocitentan 12.5 mg achieved a placebo-adjusted reduction of 3.8 mmHg in office systolic BP (SBP) at 4 weeks. In BaxHTN, baxdrostat 1 and 2 mg reduced office SBP by an additional 8.7 and 9.8 mmHg, respectively, at 12 weeks, whereas lorundrostat 50 mg achieved a 9.1-mmHg placebo-adjusted reduction at 6 weeks in Launch-HTN. The investigational RNA-interference agent zilebesiran demonstrated sustained reductions in ambulatory BP, with effects varying according to background therapy in KARDIA-2. Novel triple and quadruple single-pill combinations also yielded clinically relevant improvements in BP control. These findings suggest that newer therapies may expand treatment options for appropriately selected patients with uncontrolled or resistant hypertension. Nevertheless, their clinical incorporation should follow confirmation of genuine treatment resistance and optimization of standard therapy, with careful consideration of regulatory status, adverse effects, renal function, electrolyte disturbances, affordability, and the limited availability of drug-specific cardiovascular outcome data.

References

1.NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–980. doi:10.1016/S0140-6736(21)01330-1.

2.Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–967. doi:10.1016/S0140-6736(15)01225-8.

3.McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45:3912–4018. doi:10.1093/eurheartj/ehae178.

4.Jones DW, Ferdinand KC, Taler SJ, et al. 2025 AHA/ACC/multisociety guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Circulation. 2025;152:e114–e218. doi:10.1161/CIR.0000000000001356.

5.Davis LL, Yang E, Blyler CA, et al. Optimizing blood pressure care in patients with resistant hypertension: 2026 ACC expert consensus decision pathway. J Am Coll Cardiol. Published online October 5, 2026. doi:10.1016/j.jacc.2026.08.028.

6.Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059–2068. doi:10.1016/S0140-6736(15)00257-3.

7.Schlaich MP, Bellet M, Weber MA, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927–1937. doi:10.1016/S0140-6736(22)02034-7.

8.US National Library of Medicine. TRYVIO (aprocitentan) tablets: US prescribing information (label updated August 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfe7a2ee-612c-4aba-834a-d68e6b59a0a6. Accessed November 10, 2026.

9.Flack JM, Azizi M, Brown JM, et al. Efficacy and safety of baxdrostat in uncontrolled and resistant hypertension. N Engl J Med. 2025;393:1363–1374. doi:10.1056/NEJMoa2507109.

10.US National Library of Medicine. BAXFENDY (baxdrostat) tablets: US prescribing information (initial approval May 15, 2026; label updated August 2026). DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=b1fc1ee7-facc-4099-b3db-a4c1daeaa4be&type=display. Accessed November 10, 2026.

11.Saxena M, Laffin LJ, Borghi C, et al. Lorundrostat in participants with uncontrolled hypertension and treatment-resistant hypertension: the Launch-HTN randomized clinical trial. JAMA. 2025;334:409–418. doi:10.1001/jama.2025.9413.

12.Laffin LJ, Kopjar B, Melgaard C, et al. Lorundrostat efficacy and safety in patients with uncontrolled hypertension. N Engl J Med. 2025;392:1813–1823. doi:10.1056/NEJMoa2501440.

13.Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228–238. doi:10.1056/NEJMoa2208391.

14.Bakris GL, Saxena M, Gupta A, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331:740–749. doi:10.1001/jama.2024.0728.

15.Desai AS, et al. Add-on treatment with zilebesiran for inadequately controlled hypertension: the KARDIA-2 randomized clinical trial. JAMA. 2025;334:46–55. doi:10.1001/jama.2025.6681.

16.Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. Lancet. 2024;404:1536–1546. doi:10.1016/S0140-6736(24)01744-6.

17.Taddei S, Narkiewicz K, Bricout-Hennel S, et al. Quadruple vs triple therapy for resistant hypertension: the QUADRO trial. Eur Heart J. Published online February 11, 2026. doi:10.1093/eurheartj/ehag022.

Published

2026-11-04